Waters™

应用纪要

Empower 2 Method Validation Manager Software: Tool for Rapid Method Validation

Daniel S. Root, Andrew J. Aubin

Waters Corporation

Abstract

Empower 2 Method Validation Manager Software effectively streamlines the validation process and integrates smoothly into the validation workflow of the compliant laboratory. To illustrate the straightforward operation and comprehensive functionality of MVM, a basic assay validation of the drug product acetaminophen is summarized. Multiple screenshots from MVM are presented with the validation results to help demonstrate the application of this software to the validation process.

Benefits

- Regulatory compliance
- Straight-forward validation troubleshooting
- Data traceability
- Reduction of supervisory review
- Validation consistency

Introduction

Within the compliant laboratory, the validation of analytical methods is a fact of life. Regulatory agencies must have documented evidence that the analytical methods employed by a laboratory yield accurate and reliable results. The laboratories, utilizing advanced planning and good scientific judgment, rely on validation as a means of assuring confidence in the results generated from their analytical methods. From both perspectives, there is no argument that analytical method validation is an important process and a permanent aspect of compliant laboratory operation.

Method validation is a demanding activity. It requires a large investment in personnel,

materials, instruments, supervision, and, most of all, time. Some of the more time-consuming aspects of validation involve the creation of validation protocols and sample lists, tracking of the workflow from protocol to final reporting, the performance of calculations, and the intense need to organize and manage raw and processed data. The potential for errors in the many steps of the validation process is large and the time delay when errors occur can be costly.

Waters Empower 2 Method Validation Manager (MVM) Software, coupled with the Waters ACQUITY UPLC System, can dramatically address these time-consuming elements of analytical method validation. The advantages of using the ACQUITY UPLC System have been reported previously. MVM is designed to streamline the set-up, execution, calculation, and reporting of a method validation. It provides easy data tracking and complete organization of validation data and results monitored by the built-in oversight of automated error checking. MVM is a business-critical software that reduces the time and costs required to perform chromatographic method validation by as much as 80%. Because MVM allows the entire chromatographic method validation process to be efficiently performed within Empower 2, fewer software applications need be deployed, validated, and maintained. Software training and support is also minimized. When less software is required, the software that is

business-essential can be deployed more quickly and efficiently.

In addition, Method Validation Manager allows you to be fully compliant with governmental regulations by providing data security, a full set of user privileges, audit trails, and automatic data documentation; providing you with the necessary information and complete data traceability required for final reports and to pass audits and data reviews.

To illustrate the straightforward operation and comprehensive functionality of MVM, a basic assay validation of the drug product acetaminophen will be summarized. Multiple screenshots from MVM are presented with the validation results to help demonstrate the application of this software to the validation process.

Experimental

Materials

Acetaminophen RS was purchased from Sigma-Aldrich Co. (St. Louis, MO). Methanol was acquired from Fisher (Fair Lawn, NJ). Water was purified with a MilliQ Gradient A10 System (Millipore, Billerica, MA).

UPLC conditions

The assay was performed on a Waters ACQUITY UPLC System consisting of a Binary Solvent Manager (BSM), Sample Manager (SM), and Tunable UV Detector (TUV). A Waters ACQUITY UPLC BEH C_{18} , 1.7 µm, 2.1 X 50 mm Column was selected for the separation. All instruments were controlled, and data were collected and analyzed, using Empower 2 Method Validation Manager Software.

Assay conditions

Mobile phase:	90:10
	water/methanol,
	mixed by pump
Flow:	0.65 mL/min
_	
Temperature:	40 °C
Injection volume:	1.0 μL
injection volume.	1.0 μΕ
Wavelength:	243 nm
Runtime:	2 min
Retention time:	0.7 min

Solution preparation

The acetaminophen working standard was made from a 1:9 dilution of a 0.1 mg/mL acetaminophen stock standard. 10 mg of acetaminophen RS was weighed accurately into a 100 mL volumetric flask, diluted to mark, and mixed with mobile phase. A 1.0 mL aliquot was then transferred to a 10 mL volumetric flask, diluted to mark, and mixed with mobile phase. The final concentration of the working standard was 0.01 mg/mL acetaminophen RS.

Acetaminophen sample preparation

Sample preparations for this method were made using the following procedure:

Weigh and finely powder at least 20 tablets. Transfer an accurately weighed portion, equivalent to about 100 mg of acetaminophen, to a 200 mL volumetric flask. Add approximately 100 mL of mobile phase and shake the solution for 10 minutes, then sonicate for 5 minutes. Fill the flask to mark with mobile phase.

Transfer a 5.0 mL aliquot of the above solution to a 250 mL volumetric flask, dilute to mark with mobile phase, and mix. The final concentration of this preparation should be approximately 0.01 mg/ mL acetaminophen.

Method system suitability criteria

The method system suitability criteria are listed in Table 1.

Parameter	Acceptance Criterion
%RSD RT min	≤ 1.0%
%RSD area acetaminophen in std	≤ 2.0%
USP tailing	≤ 1.5%
USP plates	≥ 1000

Table 1. Method suitability criteria.

Acetaminophen analysis with the ACQUITY UPLC System is shown in Figure 1.




Figure 1. Analysis of acetaminophen.

Validation protocol and execution

The elements of the written validation protocol for this method were easily transferred into the validation protocol method template of MVM (Figure 2). The following validation tests were performed in this study:

- Robustness (for three factors)
- Repeatability
- Intermediate precision (different analyst)

- Linearity
- Accuracy
- Solution stability (24 hours)

	ethod Classification Compound Type: Drug Product natylical Method Type: Assay Development Phase: Development Protocol Comments:	Method/Study Approvals Validation Protocol Approval:		
	idation Tests System Precision Approvals/Sign Offs idation Tests Test Name	Test Description		Text Status
-	Robustness	Robustness 1, 4 factors	Required	Sende Sets Incondite
	Repetability	Repeatability 1	2	Sample Sets incomplete
	Linearity	Linearty 1	2	Sample Sets Incomplete
	Accuracy	Accuracy 1	2	Sample Sets incomplete
	Intermediate Precision	second analyst, different day	P	Sample Sets incomplete
	Stability	Stability 1 - 24 hour	R.	Sample Sets Incomplete
131	a Attached to Selected Test			
3	Sample S	et Method		SSM Status
	robust_flow_temp_octorg1			~
1				

Figure 2. The written protocol can be easily transferred to Empower Method Validation Manager.

Individual tests and their associated acceptance criteria were configured, as shown in Figures 3 and 4.

Accuracy Parameters	
Acquisition Processing and Acceptance Criteria	
Driteria: Exact Preparations/Levet 3 Levels: 3 Injections/Preparation: 1 Injections: 8	
Cevels	
1 80% 2 100%	
3 120%	
OK C	Cancel Help

Complete sample set methods were constructed and then saved as templates within the validation protocol method (Figure 5).

quisi	tion Pr	ocessing an	d Acceptance Cr	iteria]						
	nponent	Type · Selec Componen	t row to set Acc	eptan		ria ssessed Fi	la l	. 1	Significance		
1	Mala Ca	mponent	стуре	~ -	A: Recover		leli	0.05	1.00	Level	
H	main Co	mponent		76 P	tecover	У		0.05			
Н				-			-				
Н				+							
Н				-			_				
H							_				_
Acc			Component Type	_			_				
6	Field	і Туре	Field Name		Target	% Range	•	Lower Limit (LL)		Fault on 1	large
1	Accura	cy Result	% Recovery Me	an	100.00			95.0	0 105.00	Г	
							_				
Ц				\rightarrow			_				
Н				\rightarrow			_				
Н				\rightarrow			_				
Acc	ceptance	Criteria per	Component Type	per L	.evel						
6	Level	Field Type	Field Name	Tar	get %	6 Range	L	ower Limit (LL)	Upper Limit (UL)	Fault on T	arge
											_

Figure 5. Sample set method.

Since the validation protocol called for method suitability parameters to be met by each analysis, system precision requirements were also configured (Figure 6).

1	68 94 6				al								
0	Plater/vel	SampleName	N V01 (uL)	# cf His	Function	Method Set / Report Method	Pun Time (Minutes)	Level	Sample Preparation	Next Iry. Delay (Minutes)	enelyst	Experiment Name	Robustne
	1:0,1	test inj.	1.0	1	Inject Samples	scets_robust1	2.00	0%	-	0.00	_		F
8	1:8,2	sys prec. 100% dd	1.0	6	Inject Standards	aceta_robust1	2.00	100%		0.00			Г
	1:0,3	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 1	0.00		Experiment 1	V
6	1:0,4	100% prep	1.0	1	Inject Samples	aceta_robutf1	2.00	100%	Preparation 2	0.00		Experiment 1	R
5	1:4,5	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 3	0.00		Experiment 1	R
6	1:0,5	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 4	0.00		Experiment 1	1
2	1:0,7	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 5	0.00		Experiment 1	R
8	1:0,0	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 6	0.00		Experiment 1	1
9				1	Clear Calibration	scela, robust1							
10					Calibrate	aceta_robust1							
					Quantitate	sceta_robust1			1				
					Equilitrate	aceta.robust2	10.00			0.00			
	1:0,1	deat inj.	1.0	1	Inject Samples	aceta_robust2	2.00	0%		0.00			F
14	1:4,2	ref. abd. 100%	1.0	6	Inject Standards	aceta_robust2	2.00	100%		0.00		Experiment 3	Г
5	1.8.3	100% prep	1.0	1	Inject Samples	aceta.robust2	2.00	100%	Preparation 1	0.00		Experiment 3	1
16	1:0,4	100% prep	1.0	1	Inject Samples	aceta_robust2	2.00	100%	Preparation 2	0.00		Experiment 3	R
	1:4,5	100% prep	1.0	1	Inject Samples	aceta_robust2	2.00	100%	Preparation 3	0.00		Experiment 3	R
10	1:0.6	100% prep	1.0	1	Inject Samples	aceta.robust2	2.00	100%	Preparation 4	0.00		Experiment 3	V
19.	1:0.7	100% prep	1.0	1	Intent Stangles	aceta robust2	2.00	100%	Preparation 5	0.00		Experiment 3	P
30	1:0,0	100% prep	1.0	1	Inject Samples	aceta_robust2	2.00	100%	Preparation 6	0.00	-	Experiment 3	
21	-			1	Clear Calibration	aceta.robust2						Concession of the local division of the loca	
22					Calibrate	aceta robust2							
					Quantitate	acets_robust2							
24					Equilitrate	aceta robust3	10.00			0.00			
25	1:0.1	beat ini.	1.0	1	Inject Sangles	aceta robust3	2.00	0%		0.00			F
35	1:82	ret. abd. 100%	1.0	6	inject Standards	aceta robust3	2.00	100%		0.00		Experiment 2	F
27	1:0.3	100% prep	1.0		Inject Sangles	aceta robust3	2.00	100%	Preparation 1	0.00		Experiment 2	V
28	1:0.4	100% prep	1.0	1	Inject Sangles	aceta robust3	2.00	100%	Preparation 2	0.00	-	Experiment 2	P
29	1:8,5	100% prep	1.0	1	Inject Samples	aceta_robust3	2.00	100%	Preparation 3	0.00	-	Experiment 2	
30	1:0.6	100% prep	1.0	1	Inject Sangles	acets robust3	2.00	100%	Preparation 4	0.00		Experiment 2	R
11	1.6,7	100% prep	1.0		Rject Samples	aceta_robust3	2.00	100%	Preparation 5	0.00	-	Experiment 2	P
32	1:8,0	100% prep	1.0	- 1	Inject Samples	aceta_robust3	2.00	100%	Preparation 6	0.00	-	Experiment 2	R
33				1	Clear Calibration	aceta robust3							
34					Calbrate	aceta robust3							
35					Quantitate	Ctsudor etros							
*		-			Ex dbuto	costs estratio	10.00		1	0.00		1	

Figure 6. System precision parameters. In this protocol, the % RSD of peak area must be no more than 2%.

During the process of test configuration and sample set method construction, errors were automatically caught by MVM, as indicated by a red X in the validation protocol window. Using the update status button and responding to error messages from the message center effectively guides all troubleshooting activity (Figure 7).

Description Description Description Analysis Description Description Description Development Protocol Conservict Development Protocol Conservict Validation Tests System Precision Approxit/Sign Approxit/Sign Validation Tests System Precision Approvalue/Sign				2 3						
Compound Type: Drug Product alytical Method Type: Assay Development Phase: Development			Method/Study Validation Pro	Approvals tocol Approval:						
Acquisition Parameters			Acceptance C e - Select row	nteria lo set Acceptano	e Criteria					
System Precision Required	60		Component T	/pe		Assess	red Field		Significance Le	rvel
for all sample sets	1 Ma	in Compo	inent		Area			0.05		
Coloria:		in Compo	inent		Retention	Tine		0.05		
Exact 💌	3 Ma	in Compo	ment		USP Tellin	9		0.05		
	4 Ma	in Compo	ment		USP Plate	Count		0.05		
Viale/Sample Set 1 🛨	Accept	ance Crit	eria per Compo	ment Type						
Injections/Viat 6	60 1 Sy	Field	і Туре	Field No	rtie	Target	% Range	Lower Linit (LL) Upper Limit (UL)	Foult on Torg
	1 Sy	stem Pre	cision Result	Assessed Fie	d % RSD				2.000000	Г
Injections: 6										
	Accept	tance Cril	eria per Comp	onent Type per L	evel					
	60 L	.evel	Field Type	Field Name	Target	% Ra	nge Lov	ver Linit (LL)	Upper Linit (UL)	Fault on Targe
						-				
						1				

720002401en-f6

1				
tethod Classification Compound Type: Drug Product nalytical Method Type: Assay Development Phase: Development Protocol Comments:		Method/Study Approvals Validation Protocol Approva	ê.	
idation Tests System Precision App lidation Tests				
Test Name		Test Description	Required	Test Status
Robustness	Robustness *	 4 factors 	V	Sample Sets Incomplete
Repeatability	Repeatability	1	V	Sample Sets Incomplete
Linearity	Linearity 1		V	SS Methods incomplete
Accuracy	Accuracy 1		V	SS Methods Incomplete
Intermediate Precision	second analy	st, different day	V	Sample Sets Incomplete
Stability	Stability 1 - 2	4 hour	2	Sample Sets Incomplete
a Attached to Selected Test	Sample Set Method			SSM Status
		The red X indicates an error set method that is inconsist validation test configuration	tent with the	
FM-EMPSRV-01 - Message Center Jew Belp				E
+ +			Message	
Project Project	Assay Test Robustness 1, 4 factors E			

Figure 7. Linearity sample set method error caught by Empower 2 MVM Software. The message center indicated a problem, which was easily resolved. MVM ensured that all sample set methods were consistent with their respective test configurations. An earlier error for a robustness test configuration is also visible.

The validation protocol method was saved within a validation template project. Next, a validation working project was started and a new study was initiated based on the validation protocol method template.

The validation manager window lists the test configurations and acceptance criteria for the validation study. Additional functionality includes indicators that show test status and required approval (Figure 8). Since complete sample set methods are contained in the validation protocol method, the study can now be executed. Standards and samples were prepared then analyzed on the ACQUITY UPLC System as the previously established sample set methods.

	国 同	@ 			E) () ()			and the	
thod Classification Compound Type: Drug Product alytical Method Type: Assay Development Phase: Development Protocol Comments:			Validation Valida C	n Protocol ation Proto Overall Stu	Appr col N dy SI	rovał lame: acetamin tatus: Study Inv				
lation Tests		Test Description		Pageirad	_	Test State		VP Ctab	un 1.000	Sian Off(s)
							·	TT SLOW	40 YIL	agir Ori(s)
			•		-					
			-	1	-					
				1	_					
Intermediate Precision			t day	7	-					
Stability	Stability	1 - 24 hour		V	S	Sample Sets Inco	mplete			
Attached to Selected Test										
Sample Set Method	SSM Id	SSM Status	SSM Ap	proval SS	Sid	SS Status	SS Approval	RS Id	RS Status	RS Sign C
robust_flow_temp_pctorg		×								
	hod Classification Compound Type: Drug Product Overspreader Analy Development Phase: Development Protocal Comments: aution Tests Test Neme Test Neme Test Neme Test Neme Test Neme Secured Common Secure Common Secu	hod Classification Compound Type: Dug Picket Anay Development Protocol Comments: autom Tetts Septem Precision ApprovalueSign Offic autom Tetts Tett Name Tett Name Tett Name Construct Repeatability R	hod Classification Compound Type: Drug Product Analy Compound Type: Drug Product Analy Convergence Phase: Development Protocid Commente: autom Test: Test Neme Test Ne	hod Classification Compound Type: Drug Product Overspanned Compound Type: Drug Product Validatio Uvalidatio U	hd Charliniation Company Type: Drug Phoduct Company Type: Drug Phoduct Company Type: Drug Phoduct Validation Photo Development Photod Company Validation Photo Uvalidation Uvalidati	hd Charlifation Compound Type: Drug Podyct Middler Assay Develgement Fase: Develgement Protocid Comments: Method Study Approva Validation Notocid Develgement Protocid Comments: Method Study Approva Validation Notocid Develgement Protocid Comments: Method Study Approva Validation Notocid Develgement Protocid Comments: Method Study Approva Validation Notocid Develgement Protocid Comments: Method Study Approva Validation Notocid Develgement Protocid Comments: Method Study Approva Validation Notocid Develgements: Method Study Approva Validation Notocid De	hd Charaffadion Compound Type: Drug Podzet Method Study Approvals Valdation Photock Approvals Valdation Photock Approvals Valdation Photock Approvals Valdation Photock Approvals Valdation Study Appro	hod Classification Compound Type: Drug Picket Assay Development Phase: Development Protocid Comments: Waldwide Photocol Approval: Valdwide Photocol State Approval: Valdwide Photocol State Approval: Valdwide Photocol State State Approval: Valdwide Photocol State State Approval: Valdwide Photocol State State State State Photocol Valdwide Photocol State State State State Photocol Valdwide Photocol State State State Photocol Valdwide Photocol V	hod Classification Compound Type: Drug Picket Approval: Validation Photocol Approval: Validation Study Approval: Val	Compoord Type: Diag Podati (bold Heted Tige: A rise) Valdation Procetor Maria: Scalar Scalar Development: Valdation Pixed Status: Sudy Foodpate Interfield System Precision Approvatu/Sign Otts Scalar Scalar Valdation Pixed Status: Sudy Foodpate Valdation Study Approval Interfield System Precision Approvatur/Sign Otts Feed Status: Sudy Foodpate Valdation Study Approval YE Status: Net Precision Study Foodpate Valdation Pixed Valdation Study Approval YE Status: Net Pixed Status: Study Foodpate Valdation Study Approval YE Status: Net Pixed Status: Study Foodpate Valdation Pixed Valdation Study Approval YE Status: Net Pixed Status: Study Foodpate Valdation Pixed Valdation Study Approval YE Status: Net Pixed Status: Study Foodpate Valdation Pixed Valdation Study Approval YE Status: Status: Net Pixed Status: Study Foodpate Valdation Pixed Valdation Valdation Valdation Valdation Pixed Valdation Valdation Valdation Valdation Valdation Pixed Valdation Valdation Valdation Valdation Valdation Valdation Pixed Valdation Valdation Valdation Valdation Valdation Valdation Pixed Valdation

Figure 8. The green check mark in this validation manager window indicates that the sample set method is consistent with the user-configured test criteria.

Results and Discussion

Robustness

Robustness was evaluated using a 1/2 fractional factorial experimental design. The parameters assessed were flow rate, percent organic in the mobile phase, and column temperature (Table

2). Because the sample preparation procedure of this method is direct from the United States Pharmacopeia , only selected instrumental parameters were evaluated. The acceptance criteria for the test were:

1. The amount of acetaminophen determined must fall within 5% of the target value.

2. The %RSD of the amount must be no more than 3%.

A parameter that fails these criteria will need to be tightly controlled when performing the assay.

Experiment	Column temperature °C	%Organic	Flow rate mL/min
1	37	8	0.750
2	43	8	0.550
3	37	12	0.550
4	43	12	0.750

Table 2. Experimental design of robustness from MVM.

The results of the robustness testing indicate that all three factors – percent organic, flow rate, and column temperature – had statistically significant effects on the determination of acetaminophen by this method. Referring to the effects plot in the validation result review window in Figure 9, varying the percent organic by $\pm 2\%$, the temperature by ± 3 °C, and the flow rate by ± 0.1 mL/min, produced a 1%, 5%, and 10% effect on the assayed acetaminophen amount respectively.

16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16																
Exploration Image: State and the conjects in Boardward Accurry to the conjects in Boardwardward (CUIT) 110 / Conjects in Boardwardwardward (CUIT) 110 / Conjects in Boardwardwardwardwardwardward (CUIT) 110 / Conjects in Boardwardwardwardwardwardwardwardwardwardw	•	Factors & Interaction	C- D- A- -0.0011	-0.0010 Variance Piot			0008		2007 -0.0 Ethec and Plot /	06 1	4.0005		ia dani	-a 10005	0.002	
	VTU QUIT TTP: D. Offects Piet A Van 80 Visible Veldation Result to	Test Descrip				Сопро		essing Code	5 F	ieutes I	Experiments	Points/Experiment	Group By			
	1	V	5001	Robustness 1. :	3 190	tors Main Comp	onent	ecetami	ropilear MV28 h	V16 MV69 N	rv75	V	4	6	Experiment Non-	e
	<	► A E	flects Plot &	Variance Pict	<u>(н</u>	alf Normal Prob	ability	Pilot & To	and Piot A Robe	stness Re	A fue	rest Eff	fects 🖌 AN	IONA & Data & Pea	k Besult /]
	65	Factor	Source	55	CF.	MS	F.	Ratio	F-Ratio Reterenv	e p-Value	Verie	nce Cor	rponent %	Variance Component	E Variance Com	00
	1	٨	pct_org_mp	3.824533e-007	1	3.824533e-007	215	0.030933	6.6078	6 0.000000		0	0000000	1.18020	4	0
	2	B	col_temp	6.045435e-006	1	6.048435e-006	3464	7.634652	6.6078	0.000000	0	0	1000001	19,51913	2	0
	3	с	flow_rate	2.430504e-005	1	2.430504e-005	19922	8 100284	6.6078	0.000000		0	000002	78.60954	8	0
	н										-		_			

Figure 9. Validation test result review window. If the drug name appears in bold, red type, this indicates an out of specification result. Using the tabs of the review screen, the exact nature of the out-ofspecification result can be quickly determined.

In this case, robustness was evaluated for only the primary effects of the three factors with no consideration given to interaction. However, additional factors and the assessment of possible interactions between them, can all be performed easily and the results analyzed with MVM's powerful statistical techniques with a minimum of effort on the part of the validation analyst.

Repeatability

Repeatability (intra-assay precision) was tested by analyzing six individual sample preparations according to method conditions. The resulting 0.13% RSD for amount easily fell within the acceptance criterion of %RSD ≤2.0%, demonstrating that this assay is highly repeatable (Figure 10).




Figure 10. Repeatability test in the validation result review window.

This repeatability result was used in the intermediate precision determination and as the initial time point for the solution stability test. MVM automatically consolidates test result calculations from separate sample set methods.

Intermediate precision

Intermediate precision (ruggedness, inter-assay precision) was evaluated for a different analyst, on a different day, on a different instrument and column. Six individual sample preparations were analyzed according to method conditions. Results were compared with the repeatability determination. A difference of no more than 3.0% in the amount of acetaminophen between the two analysts was an acceptable result. The resulting 2.6% difference demonstrates the ruggedness of this assay (Figure 11).




Figure 11. Intermediate precision result shown in the validation result review window.

Accuracy

Accuracy was assessed by analyzing triplicate preparations of mobile phase spiked with acetaminophen RS at 80, 90, 100, 110, and 120% of the target concentration of the method (0.01 mg/mL). The recovery result from the spiked acetaminophen ranged from 99 to 101% and fell within the 95 to 105% acceptance range. The method is very accurate for the range tested (Figure 12).

x x > x x 2	_															
(f) Accuse(y) (j) Study - acetaminophen(2) (j) Tent Decorption: Accuse(y) 1 (j) acetaminophen % Recovery A (j) System Precision (j) Study - acetaminophen(2) (j) Study -		110.00- 000000- 00000- 0000-	8	.			-		-0			2		-		
1) acetaminophen Area ACQUIT	17	90.00-4.4	75	80	8	5 1	0	96	10	0 10	15 11	0 11	5	120	12	5
(1) acetaminophen USP Tailing A			6						Lev	el						
i) acetaminophen USP Plate Co	10	A Arcuraci	Plot (Trend	Pict /					-	1						-
		X Value	t Lower Rang	×	Value er Range	% Recovery Mean	% Recove SD	NY % Rec % P		% Recovery Mean Std Error	% Recovery Mean Cl	% Recovery Mean LCL	% Rec Me UC	m 7*	Recovery Skew	I
	1		0.00800	0 0	0.012000	100.24	0.514	120 0.1	512865	0.132745	0.284710	99.96	1	100.53	-0.861692	1
	1		0.00600	0 0	0.012000	100.24	0.514	120 0.	512885	0.132745	0.284710	99.96		100.53	-0.861692	
	1	Accuracy		E								99.96		100.53	-0.861692	
	1	Validation Result id	Plot & Trend	Plot)		Result & Le	rel Summ		(A LOat	a 🖌 Peak Res				100.53 % Recover	1	
		Validation Result Id	Plat & Trend	Plot)	Accuracy	Result & Le	rel Summ	any AANOs tertion Time (min)	(A . (Dat X Value	a <u>A Peak Res</u> X Value Field Type	ut/	PE Calculated			y % Dia	
	1	Validation Result ki \$051	Plot & Trend Component scetaminophen	Pice A	Accuracy Data Foult	Result & Le	rel Summ	ary I ANOs terition Time (min) 0.619	VA 2 Dat X Value 0.01000	Amount	pa R / Normalized We	pt Calculated	X Value	% Recover	y % Bia	12
	1	Validation Result id S051 1 S051 1 S051 1	Plat & Trend Component acetaminghen acetaminghen acetaminghen	Plot)	Accuracy Data Foul	Result & Le	rel Summ	any (ANIO) tection Time (min) 0.619 0.619 0.620	W 2 Date X Value 0.01000 0.01000	a / Peak Res X Value Field Type 0 Amount 0 Amount 0 Amount	2017. / Normalized Wes 1,0000 1,0000 1,0000	rt Calculated 00 D 00 0 00 0	X Value 009992 010023 010017	% Recover 99.5 100.2 100.1	y % Bia 12 -0.0760 13 0.2251 7 0.1760	17
	1 2 3 4	Validation Result id S051 (S051 (S051)	Plot & Trend Component iccetaningshen iccetaningshen iccetaningshen iccetaningshen	Plot). Level 100% 100% 100%	Accuracy Data Foul	Result & Le	rel Summ	ary (ANO) terition Time (min) 0.619 0.620 0.620	(A. 2 Date X. Value 0.01000 0.01000 0.01000	A Peak Res X Value Field Type Amount Amount Amount Amount	22R / Normalized Wei 1.0000 1.0000 1.0000 1.0000	PE Calculated 00 00 00 00 00 00	X Value 009992 010023 010017 011049	% Recover 993 100.2 100.1	y % Bia 2 -0.0700 3 0.2251 7 0.1740 15 0.4478	17
	1	Validation Result id 5051 (5051 (5051 (5051 (5051 (Plot & Trend Component acetaminophen acetaminophen acetaminophen acetaminophen acetaminophen	Pict A Level 100% 100% 110%	Accuracy Data Foul	Result & Le	rel Summ	any (ANIO) terition Time (min) 0.619 0.619 0.620 0.620 0.620	0.01000 0.01000 0.01000 0.01100 0.01100	X Value Field Type 0 Amount 0 Amount 0 Amount 0 Amount 0 Amount 0 Amount	22R / Normalized Wey 1,000 1,000 1,000 1,000 1,000	rt Calculated 00 00 00 00 00 00 00 00	X Volue 009992 010023 010017 011049 011015	% Recover 99.5 100.1 100.4 100.1	y % Bia 12 -0.0760 13 0.2251 7 0.1746 15 0.4476 3 0.1346	17
	1 2 3 4	Validation Result id 5051 1 5051 1 5051 1 5051 1 5051 1	Plot & Trend Component acetaninophen acetaninophen acetaninophen acetaninophen acetaninophen	Pice)	Accuracy Data Foul	Result & Le	rel Summ	800 (min) 800 (Min) 0.619 0.619 0.620 0.620 0.620 0.620	X Value 0.01000 0.01000 0.01000 0.01100 0.01100 0.01100	X Volue Feld Type Amount Amount Amount Amount Amount Amount Amount Amount Amount	Park / Normalized Wes 1,0000 1,0000 1,0000 1,0000 1,0000 1,0000	rt Calculated 00 00 00 00 00 00 00 00 00 00	X Value 009992 010023 010017 011049 011015 011084	% Recover 99.5 100.1 100.4 100.4 100.1	y % Bia 2 -0.0788 3 0.2251 7 0.1748 5 0.4478 3 0.1346 6 0.7622	17 10 37 39 34
	1 2 3 4	Validation Result id 5051 i 5051 i 5051 i 5051 i 5051 i 5051 i	Plot & Trend Component acetaminophen acetaminophen acetaminophen acetaminophen acetaminophen acetaminophen	Pice A Level 100% 100% 110% 110% 110%	Accuracy Outs Fout F	Result & Le	rel Summ	ary ANON tertion Time (min) 0.619 0.620 0.620 0.620 0.620	(A. Z Dat X Value 0.01000 0.01000 0.01100 0.01100 0.01100 0.01100	a Peak Res X Value Feld Type 0 Amount 0 Am	Park / Normalized Wes 1,0000 1,0000 1,0000 1,0000 1,0000 1,0000 1,0000	rt Calculated 00 0 0 00 0 0	X Value 009992 010023 01007 011049 011015 011084 012083	% Recover 99.5 100.1 100.4 100.1 100.3 100.5	y % Bia 2 -0.0788 3 0.2251 7 0.1748 5 0.4478 3 0.1346 6 0.7822 9 0.6917	17 10 17 10 10 10
	1 2 3 4 5 6 7	Validation Result id 5051 / 5051 / 5051 / 5051 / 5051 / 5051 / 5051 /	Plot & Trend Component acetassinophen acetassinophen acetassinophen acetassinophen acetassinophen acetassinophen	Pice A Level 100% 100% 110% 110% 110%	Ascenaco Outo Fout F F F	Result & Le	rel Summ	ary _ ANON tertion Time (min) 0.619 0.620 0.620 0.620 0.620 0.620	X Value 0.01000 0.01000 0.01000 0.01100 0.01100 0.01100	a Peak Res XValae Pekt Type 0 Anount 0 Anount	Park / Normalized Wes 1,0000 1,0000 1,0000 1,0000 1,0000 1,0000	rt Calculated 00 00 00	X Value 009992 010023 010017 011049 011015 011084	% Recover 99.5 100.1 100.4 100.4 100.1	y % Bia 2 -0.0788 3 0.2251 5 0.4478 3 0.1346 6 0.7622 9 0.6917 7 0.7730	17 10 17 10 10 17 10 10 17 10 10 17 10 10 17 10
	1 2 3 4 5 6 7 8	Velidation Result id 5055 1 5055 1 5055 1 5055 1 5055 1 5055 1 5055 1 5055 1	Plot & Trend Component acetaninghen acetaninghen acetaninghen acetaninghen acetaninghen acetaninghen acetaninghen acetaninghen acetaninghen	Pice A Level 100% 100% 110% 110% 110% 120%	Ascenaco Outo Fout F F F	Result & Le	rel Summ	Bry 2 ANON terdion Time (min) 0.619 0.620 0.620 0.620 0.620 0.620 0.620 0.620	A Value X Value 0.01000 0.01000 0.01100 0.01100 0.01200 0.01200 0.01200	a ÉPosk Res Pold Type 0 Anount 0 Anount 0 Anount 0 Anount 0 Anount 0 Anount 0 Anount 0 Anount 0 Anount 0 Anount	Normalized Wes 1,000	#t Calculated 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0	X Value 009992 010023 010017 011049 011015 011084 012083 012093	% Recover 99.5 100.2 100.4 100.4 100.3 100.8 100.3	y % Bia 2 -0.0788 3 0.2254 7 0.1746 15 0.4478 3 0.1346 6 0.7622 9 0.6917 7 0.7730 9 0.4941	17 191 377 191 377 193 377 197
	1 1 2 3 4 5 6 7 8 9	Velidation Result id 5055 1 5055 1 5055 1 5055 1 5055 1 5055 1 5055 1 5055 1	Plot & Trend Component acetaninophen acetaninophen acetaninophen acetaninophen acetaninophen acetaninophen acetaninophen acetaninophen acetaninophen acetaninophen acetaninophen acetaninophen	Pite A Level 100% 100% 110% 110% 120% 120%	Ascenaco Outo Fout F F F	Result & Le	rel Summ	Bry ANION terdion Time (min) 0.619 0.620 0.620 0.620 0.620 0.620 0.620 0.620	A Value X Value 0.01000 0.01100 0.01100 0.01100 0.01200 0.01200 0.01200 0.01200 0.01200 0.01200	a ÉPosk Res Pold Type 0 Anount 0 Anount	eaft / Normalized Wes 1,0000 1,0000 1,0000 1,0000 1,0000 1,0000 1,0000	pt Calculated 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0	X Value 009992 010023 010017 011049 011015 011084 012083 012093 012059	% Recover 99.5 100.2 100.1 100.4 100.3 100.8 100.3 100.4	y % Bia 2 -0.0788 3 0.2251 7 0.1746 15 0.4478 3 0.1346 6 0.7622 9 0.6917 7 0.7730 9 0.4941 3 0.5291	17 10 17 10 10 10 10 10 10 10 10 10 10 10 10 10

Figure 12. Accuracy validation result review window.

Linearity

Linearity was evaluated from the same experiment as the accuracy test. The results were linear with slope = 5.47×10^6 , R² = 0.999, and a y-intercept of -720.3. The method is linear within the range tested (Figure 13).




Figure 13. Linearity result shown in the validation result review window.

Stability

Stability was evaluated by the analysis of the repeatability sample preparations (N=6) after 24 hours at room temperature. The repeatability results were used as the time zero condition and were automatically used in the stability data processing. As shown in the validation results, acetaminophen sample preparations are stable for at least 24 hours (Figure 14).




Figure 14. The consolidated results of two separate sample sets are presented in the stability validation test result review window.

Validation summary

The status and final results for each of the validation tests was clearly displayed in the validation manager window. The green checks indicated tests with acceptable validation results, while the yellow triangle flagged robustness test results that fell outside the acceptance range (Figure 15).

)		1				8		S		
Method Classification Compand Type: Drug Poduct Analysical Method Type: Assay Development Phase: Development Protocol Comments:				Method Study Approval: Valdston Protocol Approval: Valdston Protocol Name: acetaminophers2 Overal Study: Study:: Study Complete Valdstorn Study Approval:						
	dation Tests System Precision Approvals	/Sign Offs								
3	dation Tests Test Name	-	Test Descriptio	n R	squired	Test Status		VR Status		VR Sion Off(s)
	Robustness	Robus	tness 1. 3 factor	rs		Test Complet	e	Δ		
	Repestability	Repea	tability 1		7	Test Complete		~		
1	Linearity	Lineari	ity 1		v	Test Complete		V		
1	Accuracy	Accuracy 1			1	Test Complete		V		
1	Intermediate Precision	secon	d analyst, differe	nt day	V	Test Complete		V		
	Stability	Stabilit	y 1 - 24 hour		7	Test Complet	e	×		
at	a Attached to Selected Test									
3	Sample Set Method	SSM Id	SSM Status	SSM Approval	SS Id	SS Status	SS Approval	RS Id	RS Status	RS Sign Off(s)
	intermediate_prec_exp1	3374	V		3436	~		3658	~	
	repeatability_assay_tablet	2733	V		2734	V		3211	v	
l										

Figure 15. The validation manager window shows that validation is complete.

The method for the assay of acetaminophen was analyzed for robustness, repeatability, intermediate precision, accuracy, linearity, and solution stability. This assay was found to be linear, accurate, repeatable, and to be accurately and precisely performed by more than one analyst. Additionally, samples prepared following the method procedure were documented as stable for 24 hours. From the robustness testing, altering the column temperature and flow rate was found to significantly affect the accuracy and precision of the method. The method will be revised to clearly state the need to control these two factors.

Conclusion

Empower 2 Method Validation Manager Software effectively streamlines the validation process and integrates smoothly into the validation workflow of the compliant laboratory.

Some of the benefits from the use of MVM are:

- Regulatory compliance: Empower 2 MVM
 Software easily meets all of the regulatory
 needs of the compliant laboratory.
- Straight-forward validation troubleshooting: The update tool/message center provides an application-directed, time-efficient troubleshooting process, reducing the time required to get the validation back on track.
- Data traceability: Out of specification results are clearly indicated and subsequent investigations are facilitated by the selfcontained, completely traceable data management capability of the MVM.
- Reduction of supervisory review: The onus of supervisory review is reduced using MVM, enabling rapid progression in the validation workflow. Potentially error-prone steps such as processing, calculation, and overall data management are all eliminated with the automatic, self-contained design of MVM. The need for any additional third party software packages is also eliminated.
- Validation consistency: The ability to create project and sample set method templates ensures consistency of validation protocols

with the guidance documents of the laboratory. This reduces errors in the execution of the protocols and increases confidence in the data acquired and the results obtained.

MVM not only effectively organizes and manages the performance of a method validation, it also delivers inarguable confidence in its results. Coupling Empower 2 Method Validation Manager Software to the ACQUITY UPLC System provides an unparalleled solution to the validation needs of a laboratory.

Featured Products

Empower 3 Method Validation Manager (MVM) < https://www.waters.com/534328> ACQUITY UPLC System < https://www.waters.com/514207> ACQUITY UPLC Tunable UV Detector < https://www.waters.com/514228>

720002401, November 2007

©2019 Waters Corporation. All Rights Reserved. 使用条款 隐私 商标 招聘 Cookie Cookie设置

沪ICP备06003546号-2 京公网安备 31011502007476号